Glamour on MSN10d
RSV Symptoms: Here’s How the Virus Shows Up Differently in Babies, Adults, and Seniors
Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...
Medscape2d
Rapid Antigen-based Testing for Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...
Yahoo Finance21d
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...
Medscape3d
Rapid Antigen-based Testing for Respiratory Syncytial Virus
as the presentation is indistinguishable from other respiratory tract infections, and epidemics often overlap. The microbiologic confirmation of RSV infection is based on detecting the virus in a ...
Business Wire21d
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...
Alaska Public Media8d
Respiratory disease season | Line One
20, 2024. (Matt Faubion/Alaska Public Media) Respiratory diseases like the flu or RSV are common during the Fall and Winter, but how do you know when your symptoms mean you should seek medical care?
Hosted on MSN10d
How long is RSV contagious? What you should know as respiratory illnesses spread
According to the CDC, flu hospitalizations have spiked 200 percent over the last four weeks, and hospitalizations for respiratory syncytial virus and COVID have surged as well. When it comes to RSV ...
Yahoo Finance23d
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...
Wall Street Journal22d
Pfizer Receives Expanded FDA Approval for RSV Vaccine
has been approved for the prevention of lower respiratory tract diseases, such as pneumonia and bronchitis, caused by respiratory syncytial virus, or RSV, in people between the ages of 18 and 59.
Alaska Public Media7d
Experts offer advice as Alaskans head deeper into respiratory disease season
(Matt Faubion/Alaska Public Media) Alaska is well into the start of respiratory disease season. That means Alaskans are getting the usual coughs, colds, COVID 19 and flus. But physicians are ...
UPI27d
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...